Assessment of KAN-101 in Celiac Disease (ACeD)
Completed · Phase 1 · Has a placebo group
Conditions studied: Celiac Disease
In brief
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
Key facts
- Study ID
- NCT04248855
- Run by
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
- People needed
- 41
- Starts
- 2020-01-21
- Expected to finish
- 2021-10-08
- Last updated by the study team
- 2024-08-06
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Anaheim Clinical Trials — Anaheim, California, United States
- Diablo Clinical Research — Walnut Creek, California, United States
- Innovative Medical Research of South Florida — Aventura, Florida, United States
- GCP Research — St. Petersburg, Florida, United States
- Tandem Clinical Research — Marrero, Louisiana, United States
- Parexel International- EPCU Baltimore — Baltimore, Maryland, United States
- West Michigan Clinical Research Center — Wyoming, Michigan, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Celiac Disease Center at Columbia University — New York, New York, United States
- North Carolina Clinical Research — Raleigh, North Carolina, United States
- Aventiv Research — Columbus, Ohio, United States
- WR-ClinSearch, LLC — Chattanooga, Tennessee, United States
- Advanced Clinical Research — West Jordan, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.